Erica Gould analyses a number of recent Cuban Trademark Office decisions issued in favour of US brand owners who had filed oppositions against applications made by trade mark pirates
Philippe Campolini and Peter Blomme review the Belgian approach to equivalents and prosecution history, and discuss whether Actavis v Eli Lilly might influence future cases
Canada’s new drug and biosimilar patent linkage system will fundamentally change the nature of proceedings. J Bradley White and Nathaniel Lipkus of Osler Hoskin & Harcourt discuss key changes of interest to life sciences companies
